On October 16, 2023, Aligos Therapeutics Entered Into Settlement Agreement With Janssen Biotech Providing For Resolution Of Previously Disclosed Action Brought By Janssen Alleging Breach Of Contract Aligos CEO, Others
Portfolio Pulse from Charles Gross
Aligos Therapeutics has entered into a settlement agreement with Janssen Biotech, resolving a previously disclosed action brought by Janssen alleging breach of contract. The agreement includes the dismissal of the action and release of Aligos, its CEO, and President from the claims. Aligos also agreed to dismiss counterclaims against Janssen.
October 18, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The settlement agreement with Janssen Biotech could potentially reduce legal uncertainties for Aligos Therapeutics.
The settlement agreement resolves the legal dispute between Aligos and Janssen, which could have had significant financial and reputational implications for Aligos. This resolution reduces these risks, potentially having a positive impact on Aligos' stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
The settlement agreement with Aligos Therapeutics could potentially reduce legal uncertainties for Janssen Biotech.
The settlement agreement resolves the legal dispute between Janssen and Aligos, which could have had significant financial and reputational implications for Janssen. This resolution reduces these risks, potentially having a positive impact on Janssen's stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100